Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
By M. Pavel, John Hainsworth, E. Baudin, M. Peeters, D. Hörsch, R. Winkler, J. Klimovsky, D. Lebwohl, V. Jehl, E. Wolin and 3 more. The Lancet, 2011
946 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Oncology
View Paper: https://www.semanticscholar.org/paper/7c5a0eac22ba8569bd6d13fdfa63d96a5252888f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Hamid Reza Pourghasemi
- Amiya Gayen
- Sungjae Park
- Chang-Wook Lee
- Saro Lee
- B. Oronsky
- P. Ma
- D. Oh
Citations in the corpus
- Assessment of Landslide-Prone Areas and Their Zonation Using Logistic Regression, LogitBoost, and NaïveBayes Machine-Learning Algorithms (2018, methodology): “The LVQ algorithm is efficiently applied in different fields for landslide susceptibility mapping [82], groundwater potential mapping [83], mineral potential mapping [84], and environmental science [84].”
- Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. (2015, background): “Within this RADIANT 2 trial, 44 primaries were of bronchial origin [167].”
- Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2020, neutral): “However, around 60% required dose reduction or treatment interruption [65, 67, 71].”
- Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas (2017, result): “3 months for octreotide LAR alone; while these results were not statistically significant, possibly due to a highly heterogeneous patient population, the suggestion was that adding everolimus to octreotide LAR leads to synergistic antiproliferative activity.(131) However, in a subgroup analysis of l”
- Everolimus for the treatment of advanced, nonfunctional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study (2015, background): “We found that the phase 3 RADIANT-2 study assessed the mTOR inhibitor everolimus in combination with octreotide longacting repeatable versus placebo plus octreotide longacting repeatable in patients with advanced neuroendocrine tumours and a history of carcinoid symptoms (Pavel et al, 2011).”